Tyra Biosciences, Inc.
NASDAQ Global SelectTotal Valuation
Tyra Biosciences, Inc. carries a market capitalization of 1.71B, placing it among publicly traded companies globally. Its enterprise value stands at 1.56B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.71B |
| Enterprise Value | 1.56B |
Share Statistics
Tyra Biosciences, Inc. currently has 59.66M shares outstanding.
| Shares Outstanding | 59.66M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 5.39 |
| P/TBV Ratio | 5.39 |
| P/FCF Ratio | -18.05 |
| P/OCF Ratio | -18.00 |
Financial Position
Tyra Biosciences, Inc. maintains a current ratio of 14.91, meaning it holds 14.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 14.91 |
| Quick Ratio | 14.38 |
| Debt / Equity | 1.58 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -45.31 |
| Return on Assets (ROA) | -42.15 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Tyra Biosciences, Inc.'s stock has gained approximately 135.99671% over the past 52 weeks. The 50-day moving average sits at 29.09, while the 200-day moving average is 30.25.
| Beta (5Y) | N/A |
| 52-Week Price Change | 135.99671% |
| 50-Day Moving Average | 29.09 |
| 200-Day Moving Average | 30.25 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -159.92M, while operating income came in at -160.46M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -160.46M |
| Pretax Income | -148.56M |
| Net Income | -148.56M |
| EBITDA | -159.92M |
| EBIT | -160.46M |
| Earnings Per Share (EPS) | -2.40 |
Balance Sheet
Tyra Biosciences, Inc. holds 353.94M in cash and equivalents against 5.58M in total debt, resulting in a net debt position of -73.83M. Total book value stands at 353.66M, with working capital of 342.35M providing operational flexibility.
| Cash & Cash Equivalents | 353.94M |
| Total Debt | 5.58M |
| Net Debt | -73.83M |
| Equity (Book Value) | 353.66M |
| Book Value Per Share | 5.93 |
| Working Capital | 342.35M |
Cash Flow
Tyra Biosciences, Inc. produced -109.65M in operating cash flow over the past twelve months. After subtracting -250,000.00 in capital expenditures, free cash flow totaled -109.90M - equivalent to -1.78 per share.
| Operating Cash Flow | -109.65M |
| Capital Expenditures | -250,000.00 |
| Free Cash Flow | -109.90M |
| FCF Per Share | -1.78 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -8.81 |
| FCF Yield | -5.54 |
Scores
Tyra Biosciences, Inc. posts an Altman Z-Score of 36.52, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 36.52 |